Abcam, ab266383, Human MTHFD2 knockout HEK-293T cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
MTHFD2 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 1 bp insertion in exon 1 and 5 bp deletion in exon 1. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 1 bp insertion in exon 1 and 5 bp deletion in exon 1

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-MTHFD2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MTHFD2 also known as methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2 is an enzyme with a mass of approximately 36 kDa. It catalyzes the conversion of methylenetetrahydrofolate to methenyltetrahydrofolate using NADP+ as a cofactor. MTHFD2 is a mitochondrial protein and is highly expressed in embryonic tissues and various cancers while showing low expression in normal adult tissues. This differential expression makes it an interesting target for cancer research.
Biological function summary
Methylenetetrahydrofolate dehydrogenase plays an important role in folate metabolism contributing to the one-carbon metabolic pathway. MTHFD2 is part of the tetrahydrofolate (THF) complex critical for DNA synthesis and repair. The enzyme supports the production of nucleotides and amino acids by providing necessary one-carbon units linking it to rapid cellular proliferation as seen in cancerous cells.
Pathways
MTHFD2 is key in connecting the folate-mediated one-carbon metabolic network to the central metabolism. It is involved in the metabolic pathways that synthesize purines and thymidylate. In these networks MTHFD2 interacts with proteins such as SHMT2 (serine hydroxymethyltransferase 2) facilitating serine to glycine conversion which is important for the provision of one-carbon donors for methylation reactions.
The upregulation of MTHFD2 strongly associates with various cancers including breast and colorectal cancers. The involvement of MTHFD2 in these cancers indicates its potential as a biomarker and therapeutic target. Through cancer-related pathways MTHFD2 shows a connection to enzymes such as ALDH1L2 (aldehyde dehydrogenase 1 family member L2) which also participates in folate metabolism and influences cancer progression.